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FIGURE 1 In-Hospital Mortality Stratiﬁed According to Electrocardiographic Patterns
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2571not complete occlusion, global subendocardial is-
chemia of the left ventricle can also cause STE-aVR.
Furthermore, serious conditions, such as shock and
cardiac tamponade, can lead to severe suben-
docardial ischemia of the left ventricle (2), resulting
in STE-aVR. In any of these conditions, patients
with STE-aVR are considered to have a poor prog-
nosis. To our knowledge, this is the ﬁrst study to
demonstrate the prognostic signiﬁcance of STE-aVR
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Particle Number Is
Associated With
Cardiovascular Events
Among Those Not
Classiﬁed Into Statin
Beneﬁt GroupsThe 2013 American Heart Association/American Col-
lege of Cardiology guideline for the treatment of
cholesterol to reduce the risk of cardiovascular dis-
ease (CVD) deﬁned 4 groups of patients who are
candidates for statin treatment (1). For those not
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2572classiﬁed into 1 of the 4 groups, additional risk factors
may be considered to inform statin therapy decisions.
We asked whether low-density lipoprotein particle
(LDL-P) levels are associated with CVD events in
patients not classiﬁed into 1 of these 4 groups.
We assessed the 1,919 participants from the pro-
spective, population-based Malmö Diet and Cancer
Study Cardiovascular Cohort (2) who would not have
been classiﬁed into 1 of the 4 statin beneﬁt groups on
the basis of their risk factor levels at study enroll-
ment. Baseline levels of LDL-P and other lipoprotein
subfractions were measured by using ion mobility, a
method that separates lipoproteins particles accord-
ing to size on the basis of the acceleration of charged
particles by an electric ﬁeld in the gas phase (3). The
association of LDL-P and lipoprotein subfraction
levels with incident CVD events (myocardial infarc-
tion, coronary revascularization, ischemic stroke, or
CVD death) were assessed in Cox proportional haz-
ards models that adjusted for established CVD risk
factors.
During a median 16.2 years of follow-up, 88 (4.6%)
of the participants had a ﬁrst incident CVD event.
LDL-P, LDL-small, and LDL-medium were all associ-
ated (p < 0.05) with incident CVD after adjustment
for age, sex, LDL-C, high-density lipoprotein cho-
lesterol (HDL-C), triglycerides, systolic and dia-
stolic blood pressures, antihypertensive medication
use, and smoking (Table 1). The risk of CVD was
2.3-fold greater among those in the top tertile of
LDL-P compared with those in the bottom tertile
(hazard ratio [HR]: 2.31, 95% conﬁdence interval
1.23 to 4.35; p ¼ 0.009). Further adjustment forTABLE 1 Association Between Lipoprotein Subfractions, Standard Lip
Per SD 2
HR 95% CI p Value HR
LDL-P 1.40 1.12–1.75 0.003 1.58
LDL–very small 1.11 0.95–1.30 0.17 1.65
LDL-small 1.22 1.02–1.45 0.03 1.63
LDL-medium 1.41 1.16–1.72 0.0007 1.72
LDL-large 1.23 0.98–1.53 0.07 1.46
IDL-small 0.91 0.70–1.18 0.47 0.86
IDL-large 1.09 0.86–1.36 0.48 1.50
VLDL-total 1.00 0.78–1.27 0.98 1.44
HDL-total 0.94 0.72–1.23 0.65 0.80
LDL-C 1.06 0.86–1.32 0.56 0.93
HDL-C 0.89 0.69–1.14 0.34 0.78
Triglycerides 1.09 0.88–1.35 0.44 1.09
ApoB 1.11 0.89–1.39 0.35 1.10
ApoA-I 0.79 0.62–1.01 0.056 1.02
Adjustments were made for age, sex, high-density lipoprotein cholesterol (HDL-C), low
pressures, antihypertensive medication use, and smoking.
Apo ¼ apolipoprotein; CVD ¼ cardiovascular disease; IDL ¼ intermediate density lipoprapolipoprotein (apo) B, apoA-I, homeostatic model
assessment–insulin resistance, C-reactive protein,
and family history of CVD did not appreciably change
the association (HR: 2.26, CI: 1.16 to 4.42; p ¼ 0.017).
Neither lipid levels (LDL-C, HDL-C, or triglycerides)
nor apoA-I or apoB levels were associated with CVD
(p > 0.05).
The absolute risk of CVD in the top tertile of LDL-P
at 10 years was 2.4% (95% CI: 1.2 to 3.6) and 5.6%
(95% CI: 3.8 to 7.4) at 15 years. Assuming that risk
reduction with statin therapy ranged from 25% (4)
to 35% (5), the number needed to treat to prevent
1 event in the top LDL-P tertile would be 119 to 167
over 10 years and 51 to 71 over 15 years.
In summary, we found that those in the top tertile
of LDL-P had w2-fold greater risk of CVD than those
in the bottom tertile after adjustment for established
risk factors, including LDL-C, HDL-C, and triglyceride
levels. The lack of signiﬁcant association of apoB
with CVD in this study, and the correspondingly
modest effect of apoB adjustment on the association
of LDL-P with CVD, may reﬂect the fact that apoB
is a measure of all very low-density lipoprotein,
intermediate-density lipoprotein, and LDL particles,
and of these, LDL was predominantly associated with
CVD in this study.
Thus, among subjects who were not classiﬁed into
1 of the 4 statin beneﬁt groups, lipoprotein sub-
fractions were independently associated with CVD.
Notably, the risk associated with LDL-P was of a
magnitude that could be useful in evaluating subjects
who could beneﬁt from risk assessment beyond
established risk factors.ids, and CVD
nd Versus 1st Tertile 3rd Versus 1st Tertile
95% CI p Value HR 95% CI p Value
0.87–2.86 0.13 2.31 1.23–4.35 0.009
0.92–2.98 0.10 2.11 1.18–3.77 0.012
0.91–2.92 0.10 2.14 1.21–3.78 0.009
0.95–3.10 0.071 2.28 1.24–4.18 0.008
0.80–2.66 0.22 2.29 1.24–4.21 0.008
0.50–1.49 0.60 0.77 0.42–1.42 0.41
0.84–2.69 0.17 1.54 0.82–2.88 0.18
0.80–2.60 0.22 1.65 0.88–3.09 0.12
0.47–1.36 0.40 0.91 0.50–1.67 0.77
0.53–1.64 0.80 1.20 0.72–2.02 0.48
0.46–1.32 0.35 0.70 0.39–1.24 0.22
0.63–1.88 0.77 1.00 0.56–1.78 1.00
0.62–1.95 0.74 1.52 0.88–2.65 0.14
0.61–1.72 0.93 0.69 0.39–1.20 0.19
-density lipoprotein cholesterol (LDL-C), triglycerides, systolic and diastolic blood
otein; LDL-P ¼ low-density lipoprotein particle; VLDL ¼ very low-density lipoprotein.
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Contribution of
Diastolic Vortex Ring to
Left Ventricular FillingWith much interest, we read the recent article by
Martínez-Legazpi et al. (1), which suggests insights
into the role of diastolic vortex formation in ﬁlling of
the left ventricle. We are delighted to see that ﬂuid
dynamics is increasing its presence in the clinical
cardiology community and contributes to animproved understanding of cardiac function as
underlined in the editorial comment (2).
The article by Martínez-Legazpi et al. (1) introduces
a technique to evaluate the contribution of the left
ventricular (LV) vortex to diastolic ﬁlling using
intraventricular velocity estimated by 2-dimensional
color Doppler echocardiography. They aimed to
quantify the percentage of diastolic ﬁlling volume
related to the LV vortex and tried to distinguish
between normal and abnormal LV function. Their
method is based on dividing the intraventricular ve-
locity ﬁeld into 2 components where one is the rota-
tional ﬂow, directly related to the presence of the LV
vortex, and the other is irrotational, a mathematical
approach known as Stokes decomposition widely
applied in ﬂuid dynamics.
Accordingly, Martínez-Legazpi et al. (1) ﬁrst iso-
lated the LV vortex and subsequently tried to adjust
the corresponding velocity to account for the presence
of the LV wall and mitral leaﬂets. Based also on the
communication that we had with some of the authors,
we understood that the method is initiated by
computing the rotational velocity under the assump-
tion that the LV wall is rigid, which should yield a zero
volume for transmitral inﬂow. However, this results in
an estimate of a new transmitral inﬂow volume that is
nonzero. Then the method repeats the same proce-
dure that always results in an inﬂow volume that is
different from the expansion volume, and this process
continues until the solution converges to a value.
One major concern with this method is that once
the LV wall is assumed to be rigid and the ventricle is
full of blood, it is physically impossible to achieve a
nonzero transmitral inﬂow volume. Similarly, when
the LV wall expands, its volume increase cannot
differ from the transmitral inﬂow volume. The fact
that these volumes differ during the individual iter-
ative steps is a direct violation of the fundamental
law of the conservation of mass, and reveals a ques-
tionable calculation in their method. This ﬂaw calls
into question the study’s methodology and subse-
quent results.
Moreover, according to the ﬂuid dynamics con-
servation laws, the role of the LV vortex in diastolic
ﬁlling volume cannot be evaluated merely by volu-
metric balances, but needs to be considered in
conjunction with the corresponding momentum
balances and intraventricular pressure gradients.
Here, the second controversial notion introduced by
Martínez-Legazpi et al. (1) stems from the decompo-
sition of the pressure gradient into a rotational and an
irrotational component. The analysis did not take into
consideration that every gradient ﬁeld is a conserva-
tive ﬁeld by deﬁnition; hence, it has no rotational
